BR0309746A - uso terapêutico de inibidores seletivos de pde10 - Google Patents
uso terapêutico de inibidores seletivos de pde10Info
- Publication number
- BR0309746A BR0309746A BRPI0309746-3A BR0309746A BR0309746A BR 0309746 A BR0309746 A BR 0309746A BR 0309746 A BR0309746 A BR 0309746A BR 0309746 A BR0309746 A BR 0309746A
- Authority
- BR
- Brazil
- Prior art keywords
- present
- selective
- relates
- disorders
- selective pde10
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 abstract 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229960001789 papaverine Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/301—Anxiety or phobic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,183 US20030018047A1 (en) | 2001-04-20 | 2002-05-03 | Therapeutic use of selective PDE10 inhibitors |
| US10/177,018 US20030032579A1 (en) | 2001-04-20 | 2002-06-20 | Therapeutic use of selective PDE10 inhibitors |
| PCT/IB2003/001684 WO2003093499A2 (en) | 2002-05-03 | 2003-04-22 | Therapeutic use of selective pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309746A true BR0309746A (pt) | 2007-03-27 |
Family
ID=29406263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0309746-3A BR0309746A (pt) | 2002-05-03 | 2003-04-22 | uso terapêutico de inibidores seletivos de pde10 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030032579A1 (https=) |
| EP (1) | EP1504118A2 (https=) |
| JP (1) | JP2005524402A (https=) |
| KR (1) | KR20040106455A (https=) |
| CN (1) | CN1668761A (https=) |
| AU (1) | AU2003222395A1 (https=) |
| BR (1) | BR0309746A (https=) |
| CA (1) | CA2484600A1 (https=) |
| HR (1) | HRP20041029A2 (https=) |
| IL (1) | IL164778A0 (https=) |
| MX (1) | MXPA04010777A (https=) |
| NO (1) | NO20044470L (https=) |
| PL (1) | PL373943A1 (https=) |
| RU (1) | RU2303259C2 (https=) |
| TW (1) | TWI269812B (https=) |
| WO (1) | WO2003093499A2 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20050945A (sr) * | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| US20070105840A1 (en) * | 2003-06-30 | 2007-05-10 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| EP1723134A2 (en) * | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| EP1755611A1 (en) * | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| KR100896380B1 (ko) * | 2005-01-07 | 2009-05-08 | 화이자 프로덕츠 인코포레이티드 | 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도 |
| AU2006218054A1 (en) * | 2005-01-12 | 2006-08-31 | Nycomed Gmbh | Novel pyrrolodihydroisoquinolines as PDE10 inhibitors |
| US20090176829A1 (en) | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CA2661850A1 (en) * | 2006-09-01 | 2008-03-06 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| US20090318385A1 (en) * | 2006-09-06 | 2009-12-24 | Yasushi Kohno | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient |
| US7786139B2 (en) * | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| JP5580192B2 (ja) * | 2007-03-27 | 2014-08-27 | オメロス コーポレーション | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
| KR20100110804A (ko) * | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| EP2227472A1 (en) * | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| BRPI0914772A2 (pt) | 2008-06-25 | 2015-10-20 | Envivo Pharmaceuticals Inc | compostos heterocíclicos 1,2-dissubstituídos |
| EP2318410A2 (en) * | 2008-07-09 | 2011-05-11 | Envivo Pharmaceuticals, Inc. | New small-molecule pde-10 inhibitors |
| AU2009279756B2 (en) | 2008-08-05 | 2015-01-29 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| TW201018682A (en) * | 2008-09-25 | 2010-05-16 | Kyorin Seiyaku Kk | Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient |
| WO2010041711A1 (ja) * | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| CN105125547A (zh) | 2009-05-07 | 2015-12-09 | 费瑞姆医药有限公司 | 苯氧基甲基杂环化合物 |
| JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| TW201111383A (en) | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| CA2765750A1 (en) | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| KR101713453B1 (ko) * | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| SG11201402134VA (en) | 2011-11-09 | 2014-06-27 | Abbvie Deutschland | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10a |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| WO2014001314A1 (en) * | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| US9464085B2 (en) | 2012-08-17 | 2016-10-11 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| WO2014041175A1 (en) | 2012-09-17 | 2014-03-20 | Abbott Gmbh & Co. Kg | Novel inhibitor compounds of phosphodiesterase type 10a |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| NZ708593A (en) | 2013-02-27 | 2018-01-26 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| EP2970258B1 (en) | 2013-03-14 | 2018-04-18 | AbbVie Deutschland GmbH & Co KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| KR20170139074A (ko) | 2015-04-24 | 2017-12-18 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| FI3846788T3 (fi) * | 2018-09-05 | 2025-12-17 | Univ Amsterdam | Pde11-estäjiä parkinsonin taudin hoitoon |
| CN110346004B (zh) * | 2019-08-16 | 2020-08-21 | 杭州山科智能科技股份有限公司 | 一种双声道超声时差法的流量测量数据融合方法 |
| CN116137811B (zh) * | 2020-06-05 | 2026-01-09 | 诺埃玛制药公司 | 用于治疗杜尔雷斯综合征的磷酸二酯酶10抑制剂的用途 |
| US12544364B2 (en) | 2020-06-05 | 2026-02-10 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
| WO2022162193A1 (en) * | 2021-01-28 | 2022-08-04 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| DE3224100A1 (de) * | 1982-06-29 | 1983-12-29 | Michael 6950 Schriesheim Long | Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen |
| NO941915L (no) * | 1993-05-25 | 1994-11-28 | Daiichi Seiyaku Co | Madikament for nervebeskyttelse |
| US5487976A (en) * | 1993-10-15 | 1996-01-30 | Cornell Research Foundation, Inc. | DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells |
| US20040152106A1 (en) * | 1999-10-07 | 2004-08-05 | Robertson Harold A. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| ATE321147T1 (de) * | 2001-07-31 | 2006-04-15 | Pfizer Prod Inc | Auf zellen gegründetes phosphodiesterase-10a- assay und sequenzen |
-
2002
- 2002-06-20 US US10/177,018 patent/US20030032579A1/en not_active Abandoned
-
2003
- 2003-04-22 PL PL03373943A patent/PL373943A1/xx not_active Application Discontinuation
- 2003-04-22 EP EP03717481A patent/EP1504118A2/en not_active Withdrawn
- 2003-04-22 HR HRP20041029 patent/HRP20041029A2/xx not_active Application Discontinuation
- 2003-04-22 BR BRPI0309746-3A patent/BR0309746A/pt not_active IP Right Cessation
- 2003-04-22 MX MXPA04010777A patent/MXPA04010777A/es unknown
- 2003-04-22 WO PCT/IB2003/001684 patent/WO2003093499A2/en not_active Ceased
- 2003-04-22 CN CNA038095335A patent/CN1668761A/zh active Pending
- 2003-04-22 AU AU2003222395A patent/AU2003222395A1/en not_active Abandoned
- 2003-04-22 JP JP2004501635A patent/JP2005524402A/ja active Pending
- 2003-04-22 KR KR10-2004-7017684A patent/KR20040106455A/ko not_active Ceased
- 2003-04-22 RU RU2004132198/15A patent/RU2303259C2/ru not_active IP Right Cessation
- 2003-04-22 CA CA002484600A patent/CA2484600A1/en not_active Abandoned
- 2003-04-28 TW TW092109924A patent/TWI269812B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/779,212 patent/US20040162294A1/en not_active Abandoned
- 2004-10-20 NO NO20044470A patent/NO20044470L/no not_active Application Discontinuation
- 2004-10-21 IL IL16477804A patent/IL164778A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1668761A (zh) | 2005-09-14 |
| AU2003222395A1 (en) | 2003-11-17 |
| CA2484600A1 (en) | 2003-11-13 |
| EP1504118A2 (en) | 2005-02-09 |
| TWI269812B (en) | 2007-01-01 |
| TW200307751A (en) | 2003-12-16 |
| MXPA04010777A (es) | 2005-03-07 |
| KR20040106455A (ko) | 2004-12-17 |
| RU2303259C2 (ru) | 2007-07-20 |
| PL373943A1 (en) | 2005-09-19 |
| IL164778A0 (en) | 2005-12-18 |
| JP2005524402A (ja) | 2005-08-18 |
| RU2004132198A (ru) | 2005-04-20 |
| NO20044470L (no) | 2004-11-04 |
| WO2003093499A2 (en) | 2003-11-13 |
| US20040162294A1 (en) | 2004-08-19 |
| US20030032579A1 (en) | 2003-02-13 |
| HRP20041029A2 (en) | 2004-12-31 |
| WO2003093499A3 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309746A (pt) | uso terapêutico de inibidores seletivos de pde10 | |
| EP1250923A3 (en) | Use of selective PDE10 inhibitors for the treatment of central nervous system disorders | |
| EP1755654A4 (en) | METHOD AND SYSTEMS FOR TREATING NEUROLOGICAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
| GT200800265A (es) | Pirido (3,2-e)piracinas, su uso como inhibidores de fosfadiesterasa 10, y procesos para prepararlas. | |
| DE602006008456D1 (de) | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen | |
| EP1133294A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, DAMAGE TO THE CENTRAL NERVOUS SYSTEM AND INFLAMMATORY DISEASES | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| BRPI0512864A (pt) | composições e métodos para o tratamento de condições e desordens oculares | |
| BR0017075A (pt) | Derivados de piridopirimidinona para tratamento de doença neurodegenerativa | |
| BR9809115A (pt) | Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt | |
| BR0111980A (pt) | Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda | |
| BRPI0413582A (pt) | compostos, composições e métodos para inibir a atividade de proteasome | |
| UY28817A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegerativos | |
| ATE443758T1 (de) | Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen | |
| BRPI0417520A (pt) | 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon | |
| AR028705A1 (es) | Bis-arilsulfonas | |
| EP1501531A4 (en) | METHOD FOR TREATING ANXIETY AND MOOD DISORDERS IN AGES | |
| ES2170176T3 (es) | Utilizacion de antagonistas de receptores de la serotonina y de la dopamina para el tratamiento de las enfermedades mentales resultantes de las enfermedades cerebrovasculares. | |
| BR0010515A (pt) | Sistema terapêutico de ministração transdérmica, processo para mascarar um odor desagrádavel e uso de um óleo essencial em um sistema terapéutico de ministração transdérmica | |
| Sromek et al. | Preliminary pharmacological evaluation of enantiomeric morphinans | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| PT1900365E (pt) | Compostos do tipo canabinóide e o seu uso para o tratamento de dermatites | |
| CR6581A (es) | Pirrolcarboxamidas fundido, receptores cerebrales gaba | |
| BR0307504A (pt) | Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal | |
| ES2184300T3 (es) | Derivados de aminoacidos utiles para tratar el accidente vascular encefalico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |